Agha, Mounzer E.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,756

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 663

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis

Haidar, G., Agha, M., Lukanski, A., Linstrum, K., Troyan, R., Bilderback, A., Rothenberger, S., McMahon, D. K., Crandall, M., Enick, P. N., et al. (2021) · Clinical Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 126

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

Lin, Y., Martin, T. G., Usmani, S. Z., Berdeja, J. G., Jakubowiak, A. J., Agha, M. E., Cohen, A. D., Deol, A., Htut, M., Lesokhin, A. M., et al. (2023) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 120

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

Agha, M. E., Cohen, A. D., Madduri, D., Cohen, Y. C., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., et al. (2021) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 30

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 25

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.

van de Donk, N. W. C. J., Agha, M. E., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W., Schecter, J. M., De Braganca, K. C., Varsos, H., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 20

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.

Einsele, H., Cohen, A. D., Delforge, M., Hillengass, J., Goldschmidt, H., Weisel, K., Raab, M.-S., Scheid, C., Schecter, J. M., De Braganca, K. C., et al. (2022) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 7